180 Life Sciences Corp. - Common Stock (ATNF)

PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 1,200,000 shares of common stock. The combined effective offering price for each share of common stock and accompanying warrants is $2.41. The warrants will have an exercise price of $2.28 per share, will be exercisable immediately, and expire on the five and a half year anniversary from the date of issuance.

PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.

PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.

PALO ALTO, CA / ACCESSWIRE / October 31, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQATNF) today announced the retention of Mr. Vaclav Vincalek as Senior Technology Consultant. An accomplished technologist with a strong record in technical leadership and strategy, Mr. Vincalek has guided numerous software businesses in areas of team development, technology systems architecture, and stakeholder communication.

PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately. Mr. Goodman brings over a decade of expertise in the software-as-a-service (SaaS) and iGaming industries, along with more than seven years of experience in executive leadership roles. Mr. Goodman's distinguished career includes contributions to several high-growth companies, successful IPOs, and extensive work in the Asia Pacific and Japan markets.

Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance Sheet

PALO ALTO, CA / ACCESSWIRE / October 16, 2024 / 180 Life Sciences Corp. (NASDAQATNF)("180" or the "Company"), today released the following letter to stockholders from its Interim Chief Executive Officer, Blair Jordan.

180 Life Sciences (NASDAQATNF) today announced that it can now fully focus on developing its new iGaming business after officially regaining compliance with Nasdaq Listing Rule 5550(b)(1) on minimum stockholders’ equity. The company announced earlier this month that it will be strategically shifting towards the growing global iGaming sector as it seeks to leverage significant opportunities and establish itself as a key player in this market. 180 recently acquired a gaming platform that integrates the latest blockchain technology, thus promising transparency, security, and trust. The platform, expected to launch during Q1 2025, will accept cryptocurrency and fiat currency. The company will also continue to advance its legacy biotechnology business.

PALO ALTO, CA / ACCESSWIRE / October 9, 2024 / 180 Life Sciences Corp. (NASDAQATNF) (the "Company" or "180"), is pleased to announce that it has received confirmation from Nasdaq that the Company has officially regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. With this important achievement, the Company can now fully focus on developing its newly announced iGaming business, while also continuing to advance its legacy biotechnology programs.

180 Life Sciences (NASDAQATNF), a clinical-stage biotechnology company, has released an update on several key initiatives, including announcing the acquisition of an advanced Gaming Technology Platform, positive progress on its Legacy CBD formulation and a strengthened balance sheet. According to the update, the company is shifting its focus as it enters the global iGaming market through its acquisition of a comprehensive intellectual property package, consisting of a complete back-end technology solution for online casino operations. In addition, the company anticipates retaining its current portfolio of biotechnology intellectual property as it reports positive study results exhibiting faster absorption and improved bioavailability for its new CBD pill formulation. 180 also noted that it expects to meet NASDAQ’s continued listing requirement, which requires maintenance of stockholders’ equity of at least $2.5 million; the company is also enhancing its financial position by settling meaningful legacy liabilities at substantial discounts and resolving certain legacy litigation matters

180 Life Sciences (NASDAQATNF) announced on Thursday its appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Jimenez, a current director of the Company, will leverage his extensive financial management experience to steer the Company’s growth and innovation in the pharmaceutical and biotechnology sectors. With a background that includes leadership roles in companies like Golden Matrix Group and Alfadan, Inc., Jimenez brings a wealth of expertise in financial reporting, management, and capital markets. He holds a BBA in Accounting and Finance from the University of Miami and an MBA in Finance & Management from Florida International University. The Company expressed gratitude to outgoing CFO Ozan Pamir for his contributions.

PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (“180” or the “Company”) is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors.

180 Life Sciences (NASDAQATNF), a clinical-stage biotechnology company, is reporting on its clinical pharmacology study designed to evaluate the uptake of cannabidiol (“CBD”) in a solid formulation that can be delivered as a pill. According to the report, the clinical trial, which was performed with Professor Avi Domb of the Hebrew University, School of Pharmacy, and Professor Elyad Davidson of Hadassah Hospital, involved 12 human participants and compared two solid formulations of CBD with Epidiolex, a U.S. Food and Drug Administration (“FDA”)-approved drug for epilepsy. The company noted that CBD has shown promise in studies on treatment of pain, post-traumatic stress disorder (“PTSD”), head trauma and other indications. However, the oral liquid delivery is not ideal, and the formulations tested by 180 Life Sciences and its collaborators in this study show potential for CBD being delivered by mouth in capsule or pill form. The company is waiting for full results from the study. “If shown via further clinical testing, 180 Life Sciences’ proprietary solid formulation for the delivery of CBD may provide medical professionals with greatly expanded options to prescribe and deliver CBD in a precisely dosed, high-uptake pill format rather than the current liquid format,” said Professor Avi Domb in the press release. “This may have potentially significant commercial market potential by avoiding the complexity associated with unpredictable liquid formulation delivery. Both physicians and patients may have broader acceptance of a solid oral pill format.”

PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced topline results from a clinical pharmacology study (the “Study”), that evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally. The clinical trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, compared two solid formulations of CBD with a U.S. Food and Drug Administration (FDA) approved drug for epilepsy, Epidiolex. The purpose of the Study was to compare the pharmokinetic (PK) profile of a generic approved CBD product, Epidiolex®, with two solid formulations. We believe this type of trial has yet to be examined in a clinical setting. For the Company’s trial, twelve volunteers received all three formulations in a crossover randomized trial.

180 Life Sciences (NASDAQATNF) today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “hearings panel”) of the Nasdaq Stock Market LLC that it has granted the company’s request for additional time to achieve compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the Equity Rule. Specifically, the hearings panel has agreed to provide the 180 Life Sciences until Sept. 20, 2024, to regain compliance with the Equity Rule and to allow the continued listing of the company’s common stock and warrants on the Nasdaq Stock Market through such date, subject to the company’s compliance with the rule on or prior to such date. “We believe the additional extension granted by the Nasdaq Hearings Panel will allow us to finish executing on our plan to regain compliance with Nasdaq’s minimum stockholders’ equity requirement,” said Blair Jordan, interim chief executive officer of the company.

PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Hearings Panel has granted the Company’s request for additional time to achieve compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below). Specifically, the Hearings Panel has agreed to provide the Company until September 20, 2024 to regain compliance with the Equity Rule and to allow the continued listing of the Company’s common stock and warrants on The Nasdaq Stock Market through such date, subject to the Company’s compliance with the Equity Rule on or prior to such date.

PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Hearings Panel has determined to grant the Company’s request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions, including filing on or before July 31, 2024, a public disclosure describing the transactions undertaken by the Company to achieve compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below) and providing an indication of its equity following those transactions.

180 Life Sciences (NASDAQATNF) today announced that it received a letter on March 13, 2024, from the Nasdaq Stock Market LLC indicating that the company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”). As detailed in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of 180 Life Sciences’ common stock was at or above $1.00 per share. Accordingly, the company has regained compliance with the Minimum Bid Price Requirement.

PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).

180 Life Sciences (NASDAQATNF), a clinical-stage biotechnology company, will conduct a reverse stock split of its outstanding shares of common stock. The ratio of the reverse stock split, which is slated to go into effect on Feb. 28 with market open, will be 1-for-19. According to the announcement, the reverse stock split, which was approved by stockholders at the company’s Feb. 16 Special Meeting of Stockholders, will reduce the number of the company’s outstanding common shares from approximately 11.3 million shares to approximately 0.6 million shares. “In connection with the reverse stock split, every 19 shares of the company’s common stock issued and outstanding as of the effective time will be automatically converted into one share of the company’s common stock,” said the company in the press release. “No change will be made to the trading symbol for the company’s shares of common stock or public warrants, ATNF and ATNFW, respectively, in connection with the reverse split. The reverse stock split is part of the company’s plan to regain compliance with the minimum bid price requirement of $1 per share required to maintain continued listing on the NASDAQ Capital Market, among other benefits.”

PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted, at market open on February 28, 2024. In connection with the Reverse Stock Split, every 19 shares of the Company’s common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company’s common stock. No change will be made to the trading symbol for the Company’s shares of common stock or public warrants, “ATNF” and “ATNFW”, respectively, in connection with the reverse split.

180 Life Sciences (NASDAQATNF) today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. According to the announcement, potential alternatives that may be explored or evaluated by 180 Life Sciences as part of this process include, but are not limited to, an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions involving the company. 180 Life Sciences does not intend to discuss or disclose further developments during this process unless and until its board of directors has approved a specific action or otherwise determined that further disclosure is appropriate.

PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value.

180 Life Sciences (NASDAQATNF), a clinical-stage biotechnology company, and its board of directors has initiated a process to evaluate potential strategic alternatives. The goal of the process is to identify ways to unlock and maximize shareholder value. According to the announcement, company officials are working with financial and legal advisors as they consider a full range of strategic, operational and financial options. The announcement noted that there is no assurance that the strategic review process will result in the approval or completion of any specific transaction or outcome, and the company has not established a timeline for completion of the review process. Company officials don’t anticipate making any additional comments regarding the process unless or until board members approve a definitive course of action or determine that additional comments are appropriate.

PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options.